Lipoprotein(a): The Inherited Risk Factor You Measure Once

Lipoprotein(a), written Lp(a) and often said aloud as "L-P-little-a," is a cholesterol-carrying particle in the blood whose concentration is roughly 90 percent or more determined by your genes and stays remarkably steady from childhood through old age. Because the level is set largely at conception and barely moves with diet, exercise, or weight, major guidelines now suggest that most adults measure it once and record the result for life. The honest caveat is that "once" works cleanly only when the number sits well above or well below the risk threshold; a borderline reading can shift on retest, which is where a single measurement deserves a second look.

What Lp(a) actually is

Picture a standard LDL particle, the familiar carrier of "bad" cholesterol, and then attach an extra protein called apolipoprotein(a) to it. That hybrid is Lp(a). The review literature describes it as proatherogenic, proinflammatory, and prothrombotic, meaning it can promote plaque buildup in artery walls, drive inflammation, and nudge the blood toward clotting. Those three properties, packaged in one particle, are why elevated Lp(a) is linked to heart attack, stroke, and narrowing of the aortic valve, independent of your LDL cholesterol.

The key word is independent. You can have textbook LDL numbers and a careful diet and still carry high Lp(a), because the two travel on different tracks. Standard cholesterol panels do not report it. It has to be ordered on purpose.

Why it is largely fixed at birth

Most cardiovascular risk factors are dials you can turn. Blood pressure, LDL cholesterol, blood sugar, and body weight all respond to lifestyle and medication. Lp(a) is different. Its concentration is governed overwhelmingly by variation in a single gene, LPA, and the peer-reviewed literature places genetic control above 90 percent, with the trait remaining stable across the lifespan and showing minimal response to environmental or lifestyle change.

This has a blunt practical consequence: the usual advice to eat better and move more, which genuinely helps LDL and blood pressure, does not meaningfully lower Lp(a). Even drug effects are limited or paradoxical. Statins, the cornerstone of LDL treatment, do not lower Lp(a) and may nudge it modestly upward, by roughly 10 to 20 percent in the review literature. PCSK9 inhibitors reduce it by roughly 20 to 30 percent, a real but partial effect. As of this writing, no approved therapy targets Lp(a) as its main job, and no completed cardiovascular outcome trial has yet reported that lowering Lp(a) reduces cardiovascular events. Several purpose-built agents are in late-stage testing, but until those results are in, an elevated result is best understood as information about inherited risk rather than a prescription.

The case for measuring once

Because the level is genetically anchored and stable, a single measurement gives a lifelong estimate of this particular slice of inherited cardiovascular risk. The 2024 National Lipid Association focused update, released in April 2024, recommends that Lp(a) be measured at least once in every adult, and it frames Lp(a) as a continuum of risk rather than a simple pass or fail. It flags levels at or above 125 nmol/L, roughly 50 mg/dL, as high risk, and levels below about 75 nmol/L, roughly 30 mg/dL, as low risk. The American College of Cardiology's feature on Lp(a) echoes the same logic: the value is stable, so one good measurement usually suffices. Around 1.5 billion people worldwide carry elevated levels, most of them unaware, which is a large population identified by a test that many have never been offered.

A high result does not change what you can do about Lp(a) itself today, but it does sharpen the whole risk picture. It can justify treating other, modifiable factors more carefully, such as driving LDL cholesterol lower and controlling blood pressure, and it can help explain a strong family history of early heart disease that standard panels leave mysterious.

The units problem

One recurring source of confusion is that Lp(a) is reported in two different units, milligrams per deciliter (mg/dL) and nanomoles per liter (nmol/L), and they do not convert by a clean fixed factor because the particle varies in size between people. The current recommendation favors isoform-insensitive assays reported in nmol/L, which count particles more consistently. When you compare a result to a threshold, confirm which unit the lab used.

The appraisal caveat: when once is not enough

Here is where a careful reading complicates the clean slogan. "Measure it once" rests on the premise that the value barely moves, and for most people that holds. A 2024 analysis of 11,669 adults from Mayo Clinic sites, with a median of about 4.5 years between tests, found that 96.4 percent of people with normal Lp(a) and 89.9 percent with high Lp(a) stayed in the same category on retest. Those are reassuring numbers at the extremes.

The trouble sits in the middle. Among people whose first result was borderline, in the 30 to 50 mg/dL range, 51.2 percent changed category on a second measurement. The authors concluded that borderline patients may genuinely need more than one measurement, particularly women, people with existing cardiovascular disease, those on statins, and those with higher LDL cholesterol. So the tidy "test once for life" rule is accurate for the clearly low and clearly high, and shakiest exactly at the decision boundary where a person is most likely to be reclassified from watchful to worried, or the reverse. Real-world variability, assay differences, and where your number happens to fall all argue for reading a single borderline result with humility rather than treating it as a verdict.

This is educational information, not medical advice. Whether and when to measure or repeat Lp(a), and what to do with the result, are decisions to make with a qualified clinician who knows your full history.